Refine by
Endoscope Processing Articles & Analysis: Older
36 news found
The partnership between the two organizations will allow One GI® physicians to leverage the AI-based technology from Iterative Scopes to standardize the endoscopic scoring process for patients and identify likely eligible patients to enroll in IBD clinical trials. ...
” The partnership will allow Gastro Health physicians to leverage Iterative Health’s AI-based technology to better standardize the endoscopic scoring process during IBD trial recruitment, streamlining the identification of likely eligible trial patients. ...
The device remains in place for 10 days, until the body’s natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. ...
BySafeHeal
EvoEndo, Inc. (“EvoEndo”), a medical device company which developed a single use system that allows for unsedated Transnasal Endoscopy (TNE), has announced the completion of an $8.4 million Series A financing round led by founding investor TLP Investment Partners LLC (TLP) and including the Sunshine Charitable Foundation and the Jill and Paul Meister family. Proceeds from the ...
ByEvoEndo
Researchers in London, Ont., are the first in the world to use a new device for feeding tube insertion that can improve patient safety and reduce the cost of health-care services. A team from Lawson Health Research Institute has partnered with CoapTech LLC, a medical device company, to study the use of the PUMA-G System. In October of last year, the medical and research teams were the first in ...
ByCoapTech
The device remains in place for 10 days, until the body’s natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. ...
BySafeHeal
Sanford, Florida (February 21, 2022) — Omega Medical Imaging, the leading innovator in AI image-guided interventional systems for hospitals and healthcare facilities around the world, announced the installation of E-View.AI interventional endoscopy systems at Orlando Health. Located in downtown Orlando, the Orlando Health Digestive Health Institute is a national and international ...
EvoEndo’s Single-Use Endoscopy System or the “EvoEndo System” eliminates the need for general anesthesia or conscious sedation during routine upper endoscopic procedures The EvoEndo System is being distributed by Micro-Tech Endoscopy USA with commercial sales slated to begin following completion of first clinical cases at several pediatric facilities EvoEndo, Inc. ...
ByEvoEndo
REVITA-T2Di is an open-label cohort evaluating Revita DMR® in patients with insulin-treated type 2 diabetes – Revita® in the T2Di cohort has been observed to be well tolerated and all patients previously on long-acting insulin have discontinued insulin therapy in the initial follow-up period – Regular updates on the extended follow-up of the REVITA-T2Di cohort in ...
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implanted first U.S. patient in the DREAM IDE pivotal study in December 2020; there are currently ...
LEXINGTON, Mass., October 27, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes (T2D), today announced the publication of an innovative new model of metabolism, the Metabolic Balance Model. The study synthesizes multiple streams of existing evidence from ...
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with a Complete ...
EvoEndo®, Inc. (“EvoEndo”), a medical device company developing systems for unsedated endoscopy, today announced the signing of a distribution agreement with Micro-Tech Endoscopy USA, Inc. (“Micro-Tech”). The agreement, whereby Micro-Tech will distribute the EvoEndo® Single-Use Endoscopy System in the US, is expected to begin pending US FDA 510(k) clearance. ...
ByEvoEndo
REVITA-T2Di study is assessing potential of outpatient Revita DMR treatment to improve glycemic control and reduce or eliminate need for daily insulin – LEXINGTON, Mass., September 1, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the activation of the tenth ...
Sanford, Florida (July 28, 2021) — Omega Medical Imaging, the leading innovator in AI image-guided interventional systems for hospitals and healthcare facilities around the world, announced the installation of the E-View.AI interventional endoscopy system at the Pali Momi Medical Center in Hawai’i. The E-View.AI represents the first AI image-guided system in the state of ...
EvoEndo Inc., (“EvoEndo” or “the Company”) a preclinical medical device company developing systems for unsedated Transnasal Endoscopy (TNE), announced it has secured $10.1M in equity financing. The funding round, which included a variety of family offices and early-stage life science investors, will be used to further EvoEndo’s innovative technology designed to help ...
ByEvoEndo
Scivita Medical will strive to build the world's leading platform for innovative products in endoscope and related fields. Scivita Medical is headquartered in Suzhou Industrial Park with R&D centers in Suzhou, China, and Tokyo, Japan, focusing on the image processing R&D and technology innovation of endoscope. ...
Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the enrollment of the first patient in a pivotal clinical trial of Revita® DMR for patients with type 2 diabetes. The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to ...
LEXINGTON, Mass., February 1, 2021 — Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced the publication of clinical results from the investigator-initiated INSPIRE clinical trial conducted in collaboration with Fractyl. The results demonstrate that a majority of patients ...
” “Fractyl's founding mission was to find a better way to treat type 2 diabetes by addressing the root cause of disease that can reverse the disease process rather than manage its symptoms. We now have data from hundreds of patients with type 2 diabetes showing the durable benefits of a single Revita treatment,” said Harith Rajagopalan, M.D., Ph.D., co-founder ...